Fig. 4.

Short-term loss of ARID3a expression impairs B lineage development but does not alter CpG-related lineage commitment in liquid cultures. HSPCs were treated as in Fig. 2 in the presence or absence of an ARID3a-specific morpholino during CpG stimulation and assessed for B lineage and myeloid lineage cell generation by flow cytometric analyses after 5 days of culture. (A) Representative flow cytometry data from one sample treated with CpG with and without ARID3a inhibiting morpholinos are shown. (B) Cumulative data show reductions in ARID3a expression frequency in CpG and morpholino-treated cultures. Total numbers of lymphoid lineage cells (C) and myeloid lineage cells (D) are shown. Each point represents one sample. Means and standard error bars are shown. Significance was assessed by paired T test, *, p < 0.014, **, p = 0.0054, ***, p = 0.0003.